Bring nanophysics at the heart of the cell
Current limitations of radiotherapy
Radiotherapy is widely used in the treatment of most oncology indications. More than 60% of cancer patients undergo radiotherapy at some point during their treatment. With surgery, radiotherapy is the standard of care for local cancer treatment, and improves the prognosis for many patients.
However, there are still significant limitations to radiotherapy in its efficacy or toxicity due to the damage it can cause to surrounding healthy tissues. As a result, many cancer patients receive a dose that is insufficient for tumor destruction.
Improving the efficacy of radiotherapy would increase the overall efficacy of cancer treatment
To meet these high unmet medical needs, Nanobiotix’s pipeline of first-in-class products aims to increase the effectiveness of radiotherapy.
This breakthrough therapeutic approach is based on physical rather than biological principles. NanoXray increases the X-rays dose energy absorption, without increasing the dose in the surrounding healthy tissues, i.e. without causing additional damages.
The NanoXray pipeline aims to address all types of cancer treated by radiotherapy
Our aim is to develop a new standard of care by transforming the radiotherapy in radiotherapy associated with nanoparticles and potentially help millions of patients.
Nanobiotix is running a global clinical development program with its lead product NBTXR3, which is tested in seven indications across Europe, the US and the Asia-Pacific Region: a registration trial in soft tissue sarcoma, and Phase I/II trials in liver cancers (HCC and liver metastases), prostate cancer, head and neck cancers and in Asia by Nanobiotix’s partner PharmaEngine, in rectal cancer and in head and neck cancers treated by radiotherapy plus chemotherapy.
NanoXray particles have an inorganic core of crystallized hafnium oxide (HfO2). The nanoparticles have an average size of 50 nm (about 3,000 times smaller than the diameter of a human hair), which enables them to enter cancer cells to generate their efficacy.
The most important feature of HfO2 is its high electron density enabling the absorption of energy provided by X-ray treatments.
HfO2 is a biologically and chemically inert material with a good safety profile that has been shown. in preclinical and clinical studies.
NanoXray nanoparticles mode of action
Once injected into the tumor, nanoparticles accumulate in cancer cells thanks to their specific size and their particular coating. Once inside the tumor, these nanoparticles absorb the ionizing radiation delivered by radiotherapy and magnify its effect locally.
This amplifies the X-ray dose delivered to the tumor, while the dose delivered to healthy tissues remains unchanged.
NanoXray products only produce an effect when exposed to radiotherapy.
NanoXray, a revolutionary approach, in the continuity of medical practice
NanoXray requires a single injection prior to the first radiotherapy cycle with no change to surgery or radiotherapy procedures. NanoXray is fully compatible with the standard radiotherapy equipment available in most hospitals throughout the world.
Several other combinations are theoretically conceivable: with chemotherapies, MAB, molecules, or immuno-oncology.